Work

Chemoimmunotherapy in Advanced, PD‐1 Refractory Cutaneous Squamous Cell Carcinoma: Insights From Two Immunocompromised Patient Cases

Year: 2025

Type: article

Abstract: Cutaneous squamous cell carcinoma (cSCC) is one of the most prevalent malignancies worldwide, and a subset of patients, particularly immunocompromised individuals, will face heightened risks of metastasis and mortality. This report examines two cases of immunocompromised patients treated with a combination of platinum- and taxane-based chemotherapy together with PD-1 inhibition, having progressed after PD-1 monotherapy. The first patient, a 54-year-old man with HIV and recurrent metastatic cSCC, had rapid progression of disease while undergoing PD-1 inhibition with cemiplimab but later achieved tumor control when treated with pembrolizumab, carboplatin, and paclitaxel. The second patient, a 36-year-old man with cystic fibrosis and a history of lung transplantation, had no signs of response to cemiplimab but experienced a partial response when treated with cemiplimab, carboplatin, and paclitaxel. These cases suggest that combining chemotherapy with PD-1 inhibition may help overcome primary resistance to PD-1 therapy in advanced cSCC.

Source: Case Reports in Oncological Medicine

DOI: 10.1155/crom/4443916

Authors: Golbarg Rahimi, Gino K. In

Institutions: University of Southern California, USC Norris Comprehensive Cancer Center

Language: English

Topic: Nonmelanoma Skin Cancer Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $790